ArticleScientific reports2026
High glucose-to-lymphocyte ratio increases the risk of delirium and all-cause mortality in intensive care unit patients.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delirium is a common acute brain dysfunction in the intensive care unit (ICU) that correlates strongly with poor patient outcomes. The glucose-to-lymphocyte ratio (GLR), as a novel marker reflecting metabolic stress and immune status, may represent a distinct biological signal of homeostatic disruption. This study aims to investigate the relationship between GLR, ICU delirium, and mortality. Using the MIMIC-IV database, we included 16,055 adult patients during their first ICU admission. A multivariable logistic regression with a nested modeling strategy (Models A–F) was applied to examine the association between GLR and delirium, adjusting for a broad range of clinical confounders and multiple established severity indices. The robustness of these findings was validated through 1:1 propensity score matching (PSM) and extensive subgroup analyses. Restricted cubic spline (RCS) analysis explored potential non-linear relationships. Cox proportional hazards models and mediation analysis with the bootstrap method were employed to evaluate mortality risks and the mediating role of delirium. Patients in the highest GLR quartile (Q4) had a 2.51-fold higher risk of delirium compared to those in the lowest quartile (Q1) (95% CI: 2.12–2.98; P < 0.001), with a significant dose-response relationship (P for trend < 0.001). In the fully saturated model (Model F), this significant association between GLR and delirium persisted (OR = 2.51, P < 0.001). These findings remained consistent after 1:1 PSM and across all pre-specified subgroups. ROC analysis demonstrated that GLR had superior discriminative performance (AUC = 0.626) compared with blood glucose alone (AUC = 0.587) or lymphocyte count (AUC = 0.603). Survival analysis indicated significantly increased 28-day (HR = 1.17), 90-day (HR = 1.22), and 1-year (HR = 1.22) mortality for high GLR (all P < 0.05). Mediation analysis confirmed that delirium partially mediated the relationship between GLR and 28-day mortality (proportion: 15.235%–19.133%). Elevated GLR is independently associated with increased risks of delirium and mortality in ICU patients. As a composite marker of metabolic-immune dysregulation, GLR provides incremental predictive value beyond established severity scores, offering a robust biological signal for early risk stratification in critical care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.